O53 Fibroid Synovial Pathotype and Tyrosine Kinase AXL Correlate with Poor Clinical Response to Certolizumab Pegol in Rheumatoid Arthritis Patients
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.